-+ 0.00%
-+ 0.00%
-+ 0.00%

As of press release, Goli Pharmaceutical-B had risen 20.66%. According to the news, Goli Pharmaceuticals announced that the 13-week phase II study evaluating the oral administration of the small molecule GLP-1 receptor agonist ASC30 to treat obesity has achieved positive top-line results.

Zhitongcaijing·12/09/2025 01:41:05
Listen to the news
As of press release, Goli Pharmaceutical-B had risen 20.66%. According to the news, Goli Pharmaceuticals announced that the 13-week phase II study evaluating the oral administration of the small molecule GLP-1 receptor agonist ASC30 to treat obesity has achieved positive top-line results.